iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer
Clinical Trials Corporate

iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer

Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced the appointment of Joanne Jenkins Lager, M.D., as Chief Medical Officer of iTeos, effective April 1, 2019.

“We are extremely pleased to welcome Dr. Lager as our Chief Medical Officer at such an exciting time at iTeos. With our Phase 1 program for our A2A receptor antagonist, EOS100850, underway and our second TIGIT antibody program entering the clinic later this year, we believe our strategic approach has the potential to overcome the significant challenges faced in the immuno-oncology field,” said Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos. “We look forward to benefiting from Joanne’s substantial oncology experience and proven clinical development leadership as we continue to design and develop our next generation immunotherapies to improve the lives of cancer patients worldwide.”

Dr. Lager joins iTeos from Sanofi, where she served as Vice President, Head of Global Oncology Development since 2014. In that capacity, she oversaw the development strategy and operations for the company’s early and late-stage clinical development portfolio including both hematologic and solid tumor malignancies. She also served as the co-lead of the Oncology Leadership Team, co-chair of the Therapeutic Area Review Committee and chair of the Oncology Protocol Review Committee. Prior to Sanofi, Dr. Lager served at GlaxoSmithKline in various levels of increasing responsibility, including as Clinical Head of the Cancer Metabolism Discovery Performance Unit. In that capacity, she oversaw the analysis of new targets and undertook early phase clinical studies of oncology drugs. Dr. Lager received her M.D. from Duke University School of Medicine and B.A. in Psychobiology from Wellesley College.

“I am joining iTeos as CMO at a transformational stage in the company’s development,” said Joanne Jenkins Lager, M.D., incumbent Chief Medical Officer of iTeos Therapeutics. “I’m excited about the potential of the company’s best-in-class programs to improve treatment for cancer patients.”

About iTeos Therapeutics

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.

For further information, please contact:

Michel Detheux,
CEO iTeos Therapeutics
info@iteostherapeutics.com

Amber Fennell, Mathew Neal, Sukaina Virji
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com

Sarah McCabe and Carl Mauch
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com

Related news

  • iTeos Therapeutics Announces New  Scientific Advisory Board Members
    A2a Inhibitor Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Announces New Scientific Advisory Board Members

    Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman,  William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer. The full SAB comprises: Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for   Integrative Cancer Research Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable. “While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.” Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.” Additional background on all SAB members can be found on the iTeos website. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US) Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
    Clinical Trials

    iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer

    First cohort of patients with advanced cancer now dosed with EOS100850 - Target enrollment of 72 patients; initial clinical data expected in Q4 2019 Gosselies, Belgium and Cambridge, MA – April 17, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, announced today the first cohort of patients has been dosed in its Phase 1/1b study with EOS100850, the Company’s investigational A2Areceptor antagonist and lead program candidate. “I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with EOS100850, our unique and specific A2Areceptor antagonist. We believe we have a potential best-in-class compound, which was carefully designed with differentiating features to maximize the therapeutic window,” said Michel Detheux, Ph.D., Co-Founder, President and Chief Executive Officer of iTeos. “The A2A pathway has emerged as one of the most exciting targets due to the emerging clinical evidence validating the important role adenosine plays in suppressing the immune response to cancer in the tumor microenvironment. EOS100850 addresses the therapeutic challenges found within this tumor microenvironment by achieving a higher degree of receptor inhibition with its PK/PD and non-brain penetrant profile and its ability to maintain potent efficacy despite increased levels of adenosine concentrations. We are optimistic that EOS100850 can restore the immune response and may control cancer for patients in multiple indications.”  About the EOS100850 Phase 1/1b Trial This state-of-the-art Phase 1/1b study of EOS100850 will include an extended translational medicine strategy with pre- and post-biopsies, which will enable researchers to identify and confirm relevant biomarkers to be used in further clinical development. Key objectives in this flexible, open-label, dose-escalation study include understanding the safety and tolerability of the compound and determining a recommended Phase 2 dose. The pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity will also be evaluated. The trial will be conducted at multiple clinical sites in Belgium, the United Kingdom and the United States and is expected to enroll 72 patients with advanced cancer. The dose escalation and dose expansion cohorts will include a comprehensive effort to evaluate the activity in specific tumor types as well as to confirm the advantageous PK/PD profile of EOS100850. Disease-specific expansion cohorts will be enrolled at the optimal Phase 2 dose.  For more information on this trial, please visit www.clinicaltrials.gov (Identifier: NCT03873883). About the iTeos Adenosine A2A Receptor Antagonist (EOS100850) The high level of adenosine in the microenvironment of many tumors plays a significant role in tumor immune evasion. The adenosine A2A receptor is the primary adenosine receptor expressed on immune cells. In the presence of adenosine, this receptor suppresses T cell activity. In preclinical studies, EOS100850, iTeos’ A2A receptor antagonist, restores T cell activity and promotes anti-tumor activity in preclinical models, as well as synergizing with several immune-checkpoint inhibitors and chemotherapy. Preliminary evidence of clinical activity has been described in kidney, lung and prostate cancer in clinical studies of A2A receptor antagonists and other agents targeting the adenosine axis. In contrast to other clinical-stage A2A receptor antagonists, EOS100850 retains high potency in the presence of elevated adenosine concentrations measured in the tumor microenvironment and is non-brain penetrant. EOS100850 has been extensively evaluated for safety, efficacy and oral bioavailability in numerous preclinical models. About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Mathew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iteos@sternir.com